ArticleMolecular therapy : the journal of the American Society of Gene Therapy2016
Prevention of Muscle Wasting by CRISPR/Cas9-mediated Disruption of Myostatin In Vivo.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- AAV-Mediated nuclear localized PGC1α4 delivery in muscle ameliorates sarcopenia and aging-associated metabolic dysfunctions.Aging cell · 2023Article
- Rheumatoid sarcopenia: loss of skeletal muscle strength and mass in rheumatoid arthritis.Nature reviews. Rheumatology · 2023Review
- Exercise attenuates angiotensinⅡ-induced muscle atrophy by targeting PPARγ/miR-29b.Journal of sport and health science · 2022Article
- Nanomedicine, a valuable tool for skeletal muscle disorders: Challenges, promises, and limitations.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2022Review
- Construction of a rAAV-SaCas9 system expressing eGFP and its application to improve muscle mass.Biotechnology letters · 2021Article
- A Vicious Cycle of Osteosarcopeniain Inflammatory Bowel Diseases-Aetiology, Clinical Implications and Therapeutic Perspectives.Nutrients · 2021Review
- Genome Editing-Mediated Utrophin Upregulation in Duchenne Muscular Dystrophy Stem Cells.Molecular therapy. Nucleic acids · 2020Article
- Improvement of muscular atrophy by AAV-SaCas9-mediated myostatin gene editing in aged mice.Cancer gene therapy · 2020Article
- CRISPR/Cas9-Mediated miR-29b Editing as a Treatment of Different Types of Muscle Atrophy in Mice.Molecular therapy : the journal of the American Society of Gene Therapy · 2020Article
- Angiotensin (1-7) Decreases Myostatin-Induced NF-κB Signaling and Skeletal Muscle Atrophy.International journal of molecular sciences · 2020Article
- Treatment of sarcopenia: the road to the future.Journal of cachexia, sarcopenia and muscle · 2018Article
- Editorial: Geriatrics in the 21st Century.The journal of nutrition, health & aging · 2018Article
- Cellular Reprogramming, Genome Editing, and Alternative CRISPR Cas9 Technologies for Precise Gene Therapy of Duchenne Muscular Dystrophy.Stem cells international · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.